Coherus Biosciences’ (NASDAQ:CHRS) adalimumab biosimilar CHS-1420 may have scope to tap into a new population of previously uncovered psoriasis patients due to the high price of AbbVie’s (NYSE:ABBV) innovator product Humira, experts said. However, they cautioned this would only happen if payers loosen their approval criteria for biologics.
Interchangeability concerns should also be settled as some dermatologists may not want to switch stable patients from Humira to CHS-1420, experts said. However, this concern may be inflated considering Humira may not even be consistent between batches due to manufacturing challenges with biologics, some experts noted.
On 8 August, Coherus reported topline Phase III results showing similarity between CHS-1420 and Humira on percent of subjects with 75% improvement in psoriasis area and severity index (PASI75) at week 12, a media release shows. A biologics license application will follow full data in 4Q16, it states.
CHS-1420 is anticipated to have peak sales of USD 1bn, assuming a 2017 US approval, 3% penetration in psoriasis and rheumatoid arthritis by 2020, and a 20% Humira discount, an analyst report shows.